All treatments
Treatment
Buffer S9b Solution for suspension for injection clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase 2, single-blinded, randomised, controlled multi-country study to evaluate the safety, reactogenicity, efficacy and immune response following sequential treatment with an anti-sense oligonucleotide (ASO) against chronic Hepatitis B (CHB) followed by chronic Hepatitis B targeted immunotherapy (CHB-TI) in CHB patients receiving nucleos(t)ide analogue (NA) therapy.
Researchers are testing a new treatment for long-term hepatitis B in people already on medication. The study will look at how safe the new treatment is and if it helps reduce the virus in the body.
For: Hepatitis B · ChronicBelgium · Italy · Germany - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A first-time-in human (FTIH), Phase I/II, randomized, multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biologicals’ HBV viral vector vaccines given in a prime-boost schedule with sequential or co-administration of adjuvanted proteins therapeutic vaccine (GSK3528869A) in chronic Hepatitis B patients (18-65 years old) well controlled under nucleo(s)tide analogue (NA) therapy.
This study is testing a new vaccine for chronic Hepatitis B in adults aged 18 to 65. We want to see how safe it is, if it causes side effects, and if it helps the body fight the virus. Participants are already managing their condition with medication.
For: Hepatitis B · ChronicBelgium · Germany · Spain